Sino Biopharmaceutical Announces Positive Phase II Trial Results for Culmerciclib at ASCO 2026
Key Highlights for Investors
- Breakthrough Data Presented: Sino Biopharmaceutical Limited (“Sino Biopharm”, 1177.HK) has announced that positive data from its Phase II clinical trial of culmerciclib (TQB3616), a first-in-class oral CDK2/4/6 inhibitor, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Targeted Patient Population: The study focused on hormone receptor-positive, HER2-negative advanced breast cancer patients who had previously been treated with CDK4/6 inhibitors and had developed resistance.
- Primary Endpoint Met: The combination of culmerciclib and fulvestrant achieved a confirmed objective response rate (ORR) of 32.4% (95% CI: 17.4–50.5, p<0.0001), surpassing expectations and the prespecified efficacy threshold.
- Durable Disease Control: The disease control rate (DCR) reached 88.2%, with a clinical benefit rate (CBR) of 82.4%. Median progression-free survival (PFS) and duration of response (DoR) were not reached at data cut-off, but a 10-month PFS rate of 61.8% was observed, indicating sustained patient benefit.
- Manageable Safety Profile: Safety was consistent with earlier studies; grade ≥3 treatment-related adverse events (TRAEs) occurred in 40% of patients. Notably, grade ≥3 neutropenia—a key safety concern with conventional CDK4/6 inhibitors—was only 5.7%, reflecting the drug’s low CDK6 inhibitory activity.
- Regulatory Advancements: Culmerciclib received NMPA approval in China in December 2025 for use with fulvestrant in patients with HR+/HER2– locally advanced or metastatic breast cancer after endocrine therapy. In April 2026, a new indication as a first-line endocrine therapy was approved. A Phase III adjuvant trial has completed patient enrollment.
- Potential Market Impact: Culmerciclib is the world’s first oral CDK2/4/6 triple inhibitor, offering a novel mechanism to overcome resistance to existing CDK4/6 inhibitors and potentially expand the addressable market for HR+/HER2– breast cancer therapies.
Details from the Phase II Study
- Study Design: Prospective, multicenter, single-arm Phase II trial (TQB3616-II-04, NCT06701818) enrolling 35 patients with HR+/HER2– advanced breast cancer who had failed CDK4/6 inhibitor plus endocrine therapy.
- Patient Characteristics: Median age 56 years, 71.4% had visceral metastases (liver 45.7%, lung 45.7%, brain 5.7%). Most had prior palbociclib (68.6%), dalpiciclib (28.6%), or ribociclib (8.6%). Over one-third (37.1%) had received prior chemotherapy, reflecting a heavily pretreated population.
- Efficacy Results: Among 34 evaluable patients:
- ORR: 32.4%
- DCR: 88.2%
- CBR: 82.4%
- Median time to response: 3.7 months
- Median PFS and DoR: Not reached at time of analysis
- 10-month PFS rate: 61.8%
- Safety Results:
- TRAEs (grade ≥3): 40.0%
- No treatment-related deaths or discontinuations
- Grade ≥3 neutropenia: 5.7%
- Mechanism of Action: By inhibiting CDK2 and CDK4 (with minimal CDK6 inhibition), culmerciclib may overcome resistance to traditional CDK4/6 inhibitors and reduce hematological toxicity, offering a key differentiation point.
What Shareholders Need to Know
- Potential Share Price Catalyst: The positive efficacy and safety data, regulatory progress, and first-in-class status of culmerciclib are significant developments that may drive investor optimism, support future revenue growth, and positively influence Sino Biopharm’s share price.
- Competitive Advantage: Culmerciclib’s differentiated profile (dual pathway inhibition, lower toxicity) could position Sino Biopharm as a leader in the post-CDK4/6 inhibitor breast cancer treatment landscape and potentially gain market share from existing therapies.
- Pipeline Momentum: The completion of Phase III enrollment for adjuvant therapy signals near-term catalysts, further bolstering the company’s growth prospects.
Conclusion
Sino Biopharmaceutical’s announcement of strong Phase II results for culmerciclib, coupled with recent regulatory wins and a differentiated product profile, marks a pivotal moment for the company. Shareholders should closely monitor further updates, as these developments could materially impact the company’s valuation and future growth trajectory.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making investment decisions. The information is based on public disclosures as of June 2, 2026, and may be subject to change.
【廣東話版本】
中國生物製藥Culmerciclib第二期臨床試驗數據於ASCO 2026發表，展現突破性成果
投資者重點摘要
- 突破性臨床數據：中國生物製藥（1177.HK）宣佈公司旗下創新藥物Culmerciclib（TQB3616），全球首款口服CDK2/4/6三重抑制劑，第二期臨床試驗正面數據於2026年美國臨床腫瘤學會（ASCO）年會發表。
- 針對耐藥患者：試驗對象為已接受CDK4/6抑制劑治療後出現耐藥的荷爾蒙受體陽性、HER2陰性晚期乳腺癌病人。
- 主要終點達標：與fulvestrant聯合治療的Culmerciclib組合，客觀緩解率（ORR）達32.4%（95% CI: 17.4–50.5, p<0.0001），超預期並達到預設標準。
- 持久疾病控制：疾病控制率（DCR）達88.2%，臨床獲益率（CBR）達82.4%。中位無惡化生存期（PFS）及緩解持續時間（DoR）未達，到10個月時PFS率為61.8%，顯示療效持久。
- 安全性良好：安全數據與早前一致，40%患者出現三級或以上治療相關不良事件（TRAEs），但三級或以上中性粒細胞減少只佔5.7%，反映Culmerciclib對CDK6抑制力低，降低骨髓抑制風險。
- 監管進展：2025年12月已獲中國國家藥監局（NMPA）批准與fulvestrant聯合治療，適用於HR+/HER2–晚期乳腺癌的內分泌治療後患者。2026年4月再獲批作為一線內分泌治療。三期輔助治療試驗已完成入組。
- 潛在市場影響：Culmerciclib為全球首款口服CDK2/4/6三重抑制劑，創新機制有望克服現有CDK4/6抑制劑耐藥問題，擴大HR+/HER2–乳癌治療市場。
臨床試驗數據詳情
- 研究設計：多中心、前瞻性、單臂第二期臨床（TQB3616-II-04，NCT06701818），共納入35名HR+/HER2–晚期乳癌經CDK4/6抑制劑失效患者。
- 患者分佈：中位年齡56歲，71.4%有臟器轉移（肝、肺各45.7%、腦5.7%），大多數曾用palbociclib（68.6%）、dalpiciclib（28.6%）、ribociclib（8.6%）。37.1%曾接受化療，屬高難度治療人群。
- 療效結果：34位可評估患者中：
- ORR：32.4%
- DCR：88.2%
- CBR：82.4%
- 中位緩解時間：3.7個月
- 中位PFS/DoR：未達
- 10個月PFS率：61.8%
- 安全性數據：
- 三級或以上TRAEs：40.0%
- 無因不良反應導致死亡或停藥
- 三級或以上中性粒細胞減少：5.7%
- 作用機制：同時抑制CDK2及CDK4（對CDK6抑制力低），有望克服傳統CDK4/6抑制劑耐藥並減少血液毒性，具明顯優勢。
股東需知及潛在影響
- 潛在股價催化劑：療效及安全性優於預期，監管進展迅速，加上全球首創機制，有望推動投資者信心及未來收入增長，利好股價表現。
- 競爭優勢明顯：產品機制及安全性優於同類藥物，助中國生物製藥在耐藥乳癌治療領域搶佔先機，擴大市場份額。
- 產品線推進順利：三期輔助治療已完成入組，臨近重要里程碑，進一步增強公司增長動力。
總結
中國生物製藥Culmerciclib的第二期臨床數據及近期監管進展，顯示公司在乳癌創新療法領域的領導地位。股東應密切關注後續進展，因這些成果或對公司估值及未來增長產生重大影響。
免責聲明：本文章僅作資訊參考，不構成任何投資建議。投資者應自行研究或諮詢理財顧問後作出決定。本文基於截至2026年6月2日公開資料，資訊或有更改。
